OnKure Therapeutics Inc. Class A Common Stock (OKUR)

About OKUR

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, in…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

45

Website

onkuretherapeutics.com/

Fundamentals

1-day range

$3.68$4.02

Market cap

$162.39M

P/E (trailing)

—

P/E (forward)

-2.48

EPS (trailing)

$-3.50

Dividend yield

—

Beta

0.09

Avg. volume

288.5K

Forecasts

4 analyst ratings

OnKure Therapeutics Inc. Class A Common Stock Competitors

Chosen by industry and closest market cap.

• OKUR

  OnKure Therapeutics Inc. Class A Common Stock

  $3.78

  ▼ 1.31%
  Market cap $162.39MP/E —
  $2.23$5.38
• LFCR

  Lifecore Biomedical Inc. Common Stock

  $4.58

  ▲ 0.88%
  Market cap $164.67MP/E —
  $3.63$8.98
• AARD

  Aardvark Therapeutics Inc. Common Stock

  $5.71

  ▼ 13.75%
  Market cap $154.94MP/E —
  $3.35$17.94
• KRRO

  Korro Bio Inc. Common Stock

  $12.94

  ▼ 2.41%
  Market cap $154.90MP/E —
  $5.2$55.89
• TNXP

  Tonix Pharmaceuticals Holding Corp. Common Stock

  $13.59

  ▲ 0.18%
  Market cap $170.01MP/E —
  $9.4$34.04
• CNTN

  Canton Strategic Holdings Inc. Common Stock

  $2.23

  ▼ 5.32%
  Market cap $154.25MP/E —
  $1.75$7.25
• ARCT

  Arcturus Therapeutics Holdings Inc. Common Stock

  $15.19

  ▼ 6.06%
  Market cap $170.54MP/E —
  $5.5$24.17

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Oppenheimer Reiterates Outperform on OnKure Therapeutics, Lowers Price Target to $14
  benzinga · 8/14/2026
• Oppenheimer Reiterates Outperform on OnKure Therapeutics, Lowers Price Target to $14
  Benzinga · 8/14/2026
• Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News
  SeekingAlpha · 8/10/2026
• CORRECTION: OnKure Therapeutics Q2 EPS $(0.31) Beats $(0.54) Estimate
  Benzinga · 8/4/2026
• OnKure Therapeutics Announces Registration Of Up To $100M At-The-Market Offering Of Class A Common Stock Through Leerink Partners
  Benzinga · 8/4/2026

• Hartley Dylan · August 7, 2026 · Grant

  137.6K
• Hartley Dylan · August 7, 2026 · Disposition

  137.6K
• Hartley Dylan · August 7, 2026 · Grant

  50.0K
• Phillips Andrew John · August 7, 2026 · Grant

  22.4K
• Jansen Valerie Malyvanh · August 7, 2026 · Grant

  22.4K
• Agresta Samuel · August 7, 2026 · Grant

  131.4K
• Agresta Samuel · August 7, 2026 · Disposition

  131.4K
• Agresta Samuel · August 7, 2026 · Grant

  18.6K
• Agresta Samuel · August 7, 2026 · Disposition

  18.6K
• Agresta Samuel · August 7, 2026 · Grant

  50.0K
• Jason A. Leverone · August 7, 2026 · Grant

  130.6K
• Jason A. Leverone · August 7, 2026 · Disposition

  130.6K
• Jason A. Leverone · August 7, 2026 · Grant

  5.3K
• Jason A. Leverone · August 7, 2026 · Disposition

  5.3K
• Jason A. Leverone · August 7, 2026 · Grant

  5.8K

Institutional Ownership

March 31, 2026

Total shares held

27.24M

Total value held

$112.37M

Institutional holders

47